Thymopentin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Thymopentin
- DrugBank Accession Number
- DB11996
- Background
Thymopentin has been used in trials studying the treatment and prevention of HIV Infections and Hepatocellular Carcinoma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 679.776
Monoisotopic: 679.365324194 - Chemical Formula
- C30H49N9O9
- Synonyms
- Thymopentin
- Thymopentine
- Thymopentinum
- Timopentina
- External IDs
- ORF 15244
- ORF-15244
- TP-5
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- L03AX09 — Thymopentin
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- O3Y80ZF13F
- CAS number
- 69558-55-0
- InChI Key
- PSWFFKRAVBDQEG-XXTQFKTOSA-N
- InChI
- InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24?/m0/s1
- IUPAC Name
- (3S)-3-[(2S)-6-amino-2-[(2S)-2-amino-5-[(diaminomethylidene)amino]pentanamido]hexanamido]-3-[(1-{[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl)carbamoyl]propanoic acid
- SMILES
- CC(C)C(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 451417
- PubChem Substance
- 347828316
- ChemSpider
- 26232604
- 40230
- ChEBI
- 135870
- ChEMBL
- CHEMBL156025
- Wikipedia
- Thymopentin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 3 Unknown Status Prevention Hepatocellular Carcinoma 1 2 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 2 Not Yet Recruiting Treatment Carcinoma / Solid Tumors 1 Not Available Completed Treatment Human Immunodeficiency Virus (HIV) Infections 5
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0662 mg/mL ALOGPS logP -3.3 ALOGPS logP -6.3 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 3.2 Chemaxon pKa (Strongest Basic) 11.29 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 11 Chemaxon Polar Surface Area 327.67 Å2 Chemaxon Rotatable Bond Count 22 Chemaxon Refractivity 171.76 m3·mol-1 Chemaxon Polarizability 70.84 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 20, 2016 21:09 / Updated at March 31, 2023 20:25